Importance:
Short-term studies show that bariatric surgery causes remission of diabetes. The long-term outcomes for remission and diabetes-related complications are not known.
Objectives:
To determine the long-term diabetes remission rates and the cumulative incidence of microvascular and macrovascular diabetes complications after bariatric surgery.
Design, Setting, And Participants:
The Swedish Obese Subjects (SOS) is a prospective matched cohort study conducted at 25 surgical departments and 480 primary health care centers in Sweden. Of patients recruited between September 1, 1987, and January 31, 2001, 260 of 2037 control patients and 343 of 2010 surgery patients had type 2 diabetes at baseline. For the current analysis, diabetes status was determined at SOS health examinations until May 22, 2013. Information on diabetes complications was obtained from national health registers until December 31, 2012. Participation rates at the 2-, 10-, and 15-year examinations were 81%, 58%, and 41% in the control group and 90%, 76%, and 47% in the surgery group. For diabetes assessment, the median follow-up time was 10 years (interquartile range [IQR], 2-15) and 10 years (IQR, 10-15) in the control and surgery groups, respectively. For diabetes complications, the median follow-up time was 17.6 years (IQR, 14.2-19.8) and 18.1 years (IQR, 15.2-21.1) in the control and surgery groups, respectively.
Interventions:
Adjustable or nonadjustable banding (n = 61), vertical banded gastroplasty (n = 227), or gastric bypass (n = 55) procedures were performed in the surgery group, and usual obesity and diabetes care was provided to the control group.
Main Outcomes And Measures:
Diabetes remission, relapse, and diabetes complications. Remission was defined as blood glucose <110 mg/dL and no diabetes medication.
Results:
The diabetes remission rate 2 years after surgery was 16.4% (95% CI, 11.7%-22.2%; 34/207) for control patients and 72.3% (95% CI, 66.9%-77.2%; 219/303) for bariatric surgery patients (odds ratio [OR], 13.3; 95% CI, 8.5-20.7; P < .001). At 15 years, the diabetes remission rates decreased to 6.5% (4/62) for control patients and to 30.4% (35/115) for bariatric surgery patients (OR, 6.3; 95% CI, 2.1-18.9; P < .001). With long-term follow-up, the cumulative incidence of microvascular complications was 41.8 per 1000 person-years (95% CI, 35.3-49.5) for control patients and 20.6 per 1000 person-years (95% CI, 17.0-24.9) in the surgery group (hazard ratio [HR], 0.44; 95% CI, 0.34-0.56; P < .001). Macrovascular complications were observed in 44.2 per 1000 person-years (95% CI, 37.5-52.1) in control patients and 31.7 per 1000 person-years (95% CI, 27.0-37.2) for the surgical group (HR, 0.68; 95% CI, 0.54-0.85; P = .001).
Conclusions And Relevance:
In this very long-term follow-up observational study of obese patients with type 2 diabetes, bariatric surgery was associated with more frequent diabetes remission and fewer complications than usual care. These findings require confirmation in randomized trials. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01479452.
Citing Articles
Modern Trends of Drain Placement in Primary Bariatric Surgery: An MBSAQIP Analysis of 526,723 Patients.
Meyer D, Jatana S, Birch D, Switzer N, Karmali S, Mocanu V
Obes Surg. 2025; .
PMID: 40035985
DOI: 10.1007/s11695-025-07760-5.
MiRNAs as biomarkers of nutritional therapy to achieve T2DM remission in patients with coronary heart disease: from the CORDIOPREV study.
Alcala-Diaz J, Camargo A, Vals-Delgado C, Leon-Acuna A, Garcia-Fernandez H, Arenas-de Larriva A
Nutr Diabetes. 2025; 15(1):7.
PMID: 39987252
PMC: 11846967.
DOI: 10.1038/s41387-025-00362-1.
Flap Valve-Preserving Vertical Sleeve Gastrectomy (INNOVATE-VSG): Clinical Trial Study Protocol.
Nguyen N, Gadde K, Mittal R
Obes Surg. 2025; 35(3):1063-1069.
PMID: 39985715
PMC: 11906530.
DOI: 10.1007/s11695-025-07675-1.
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus.
Gorgojo-Martinez J
J Clin Med. 2025; 14(3).
PMID: 39941348
PMC: 11818433.
DOI: 10.3390/jcm14030678.
Improvement of Microvascular Function in Patients with Morbid Obesity After Bariatric Surgery Revealed by Imaging Photoplethysmography.
Vasilieva M, Kashchenko V, Shmidt E, Mizeva I, Dolotovskaya P, Zaytsev V
Obes Surg. 2025; 35(3):1001-1008.
PMID: 39934520
DOI: 10.1007/s11695-025-07741-8.
The impact of weight loss after bariatric surgeries on the patient's body image, quality of life, and self-esteem.
Abokhozima A, Zidan M, Altabbaa H, Selim A, Alokl M, Mourad M
Langenbecks Arch Surg. 2025; 410(1):24.
PMID: 39755894
PMC: 11700042.
DOI: 10.1007/s00423-024-03568-6.
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2025.
Diabetes Care. 2024; 48(Supplement_1):S86-S127.
PMID: 39651983
PMC: 11635047.
DOI: 10.2337/dc25-S005.
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025.
Diabetes Care. 2024; 48(Supplement_1):S167-S180.
PMID: 39651976
PMC: 11635032.
DOI: 10.2337/dc25-S008.
Comparative Effect of Insulin Resistance Reduction and Hormonal Alterations on Type 2 Diabetes Remission After Bariatric Surgery.
Shestakova E, Stafeev I, Yashkov Y, Yurasov A, Tomilova A, Parfyonova Y
J Clin Med. 2024; 13(22).
PMID: 39598143
PMC: 11595085.
DOI: 10.3390/jcm13226998.
Identifying Key Moments in Type 2 Diabetes Management: A Qualitative Study of the Experiences of People With Type 2 Diabetes and Diabetes Health Coaches.
Joyce J, Newbert C, Guess N, Fryer K, Mitchell C, Bespala L
Health Expect. 2024; 27(6):e70108.
PMID: 39572877
PMC: 11581956.
DOI: 10.1111/hex.70108.
The Effects of Laparoscopic Sleeve Gastrectomy on Body Mass Index (BMI) and Glycated Hemoglobin (HbA1c) Levels.
Alayed K, AlKhawashki A, Mokhtar A, Alnafisah R, Alammari K, Alsharif M
Cureus. 2024; 16(10):e70695.
PMID: 39493036
PMC: 11530244.
DOI: 10.7759/cureus.70695.
Association between delay in diabetes development and mortality in people with obesity: Up to 33 years follow-up of the prospective Swedish Obese Subjects study.
Carlsson L, Carlsson B, Jacobson P, Andersson-Assarsson J, Karlsson C, Kristensson F
Diabetes Obes Metab. 2024; 27(1):238-246.
PMID: 39434432
PMC: 11618289.
DOI: 10.1111/dom.16010.
Continuous Glucose Monitoring Captures Glycemic Variability After Roux-en-Y Gastric Bypass in Patients with and Without Type 2 Diabetes Mellitus: A Prospective Cohort Study.
Quevedo R, de Melo M, Cercato C, Fernandes A, Dantas A, Santo M
Obes Surg. 2024; 34(8):2789-2798.
PMID: 39001983
DOI: 10.1007/s11695-024-07358-3.
Assessment of arterial supply to the stomach after bariatric surgery using multidetector CT arteriography.
Khalil A, Gomez E, Gowda P, Weinstein R, Eberly H, Prologo F
Abdom Radiol (NY). 2024; 49(12):4198-4208.
PMID: 38951233
DOI: 10.1007/s00261-024-04467-6.
Bariatric surgery modulates plasma levels of antibodies against angiotensin II type 1 and endothelin 1 type A receptor in severe obesity.
Di Vincenzo A, Granzotto M, Trevellin E, Purificati C, Vecchiato M, Foletto M
J Endocrinol Invest. 2024; 48(1):191-199.
PMID: 38900373
DOI: 10.1007/s40618-024-02412-4.
Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality.
Dicker D, Sagy Y, Ramot N, Battat E, Greenland P, Arbel R
JAMA Netw Open. 2024; 7(6):e2415392.
PMID: 38848064
PMC: 11161844.
DOI: 10.1001/jamanetworkopen.2024.15392.
Changes in Symptoms and General Well-being After Reversal of Roux-en-Y Gastric Bypass: A Questionnaire Survey.
Gribsholt S, Madsen L, Poulsen I, Bruun J, Richelsen B
Obes Surg. 2024; 35(1):33-39.
PMID: 38811426
PMC: 11717792.
DOI: 10.1007/s11695-024-07321-2.
Overnutrition, Hyperinsulinemia and Ectopic Fat: It Is Time for A Paradigm Shift in the Management of Type 2 Diabetes.
Janssen J
Int J Mol Sci. 2024; 25(10).
PMID: 38791525
PMC: 11121669.
DOI: 10.3390/ijms25105488.
One anastomosis gastric bypass ameliorates diabetic nephropathy via regulating the GLP-1-mediated Sirt1/AMPK/PGC1α pathway.
Han L, Chen X, Wan D, Xie M, Ouyang S
Clin Exp Nephrol. 2024; 28(10):1051-1061.
PMID: 38782822
DOI: 10.1007/s10157-024-02516-4.
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?.
Gogineni P, Melson E, Papamargaritis D, Davies M
Expert Opin Pharmacother. 2024; 25(7):801-818.
PMID: 38753454
PMC: 11195668.
DOI: 10.1080/14656566.2024.2356254.